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Abstract 
Intermittent claudication (IC) is a classic symptom of peripheral artery disease, with first line treatment being supervised 
exercise therapy (SET). Despite this, SET is frequently underutilised, and adherence is often poor. An alternative option 
are home-based exercise programmes (HBEP). Although HBEPs are well tolerated, to the authors’ knowledge, no 
research has assessed their safety. The aim of this review was to assess the safety of HBEPs in people living with IC. We 
performed an electronic search of the MEDLINE, CINAHL, and Cochrane Library databases. The main parameter of 
interest was complication rate, calculated as the number of related adverse events per patient-hours. Subanalysis was 
undertaken to determine differences in safety for studies that did and did not include pre-exercise cardiac screening, 
and for studies with exercise at low, moderate, and high levels of claudication pain. Our search strategy identified 8693 
results, of which 27 studies were included for full review. Studies included 1642 participants completing 147,810 patient-
hours of home-based exercise. Four related adverse events were reported, three of which were cardiac in origin, giving 
an all-cause complication rate of one event per 36,953 patient-hours. Three of these events occurred following exercise 
to high levels of claudication pain, and one occurred with pain-free exercise. All four events occurred in studies without 
cardiac screening. Based on the low number of related adverse events, HBEPs appear to be a safe method of exercise 
prescription for people with IC. Our results strengthen the rationale for providing alternative exercise options for this 
population. PROSPERO Registration No.: CRD42021254581 
Keywords 
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Background 
Peripheral artery disease (PAD) affects over 236 million 
people worldwide.1 Intermittent claudication (IC) is a clas-
sic symptom of PAD, defined as calf pain or discomfort 
induced by exertion which is relieved by rest.2 IC is associ-
ated with an increased risk of mortality,3 and reductions in 
quality of life,4 functional ability,5 and physical activity 
behaviour.6 
National and international guidelines recommend super-
vised exercise therapy (SET) as first line treatment for IC.7,8 
Structured SET has shown improvements in peak oxygen 
consumption, pain-free and maximal walking distances, 
and quality of life.9,10 Despite strong evidence demonstrat-
ing the benefits of SET, its availability, adherence, and 
uptake remain low,11–13 especially in the US, when com-
pared to antiplatelet therapy, statins, and smoking cessa-
tion.14 Commonly cited barriers include time constraints, 
travel difficulties, and other personal commitments.15,16 
To improve the access and availability of exercise pro-
grammes for people with IC, studies have investigated the 
Although HBEPs are well tolerated and have shown 
improvements in walking performance,17 to our knowl-
edge, no research has assessed their safety. Supervised 
exercise therapy has already been deemed safe for those 
with IC, with a low complication rate and with no need for 
prior cardiac screening.18 Unlike SET in a clinical setting or 
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part of an exercise referral scheme, there is no direct super-
vision from a health or fitness professional when undertak-
ing a HBEP, which may increase the risk of exercise-related 
complications and compromise safety. Some HBEPs 
involve remote exercise monitoring, such as with activity 
watches or telephone contact, which improves the effec-
tiveness of HBEPs,17 but does not necessarily monitor par-
ticipant safety. 
The aim of this review, therefore, was to assess the 
safety of HBEPs in people living with IC by calculating a 
complication rate. 
Methods 
This review was conducted in line with the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.19 The systematic review 
was registered with PROSPERO (Registration No.: 
CRD42021254581). 
Eligibility 
We included studies that investigated the effects of HBEPs
in people diagnosed with symptomatic IC secondary to PAD
(Fontaine II / Rutherford 1–3). Studies that included other
PAD subgroups, such as asymptomatic individuals, were
only included where specific data were obtained on the IC
subgroup. We included studies examining HBEPs alone, in
comparison to other forms of exercise or to nonexercise
controls. Both randomised and nonrandomised studies were
included. Studies were limited to those in humans and writ-
ten in English. There was no restriction on publication date. 
Search 
We performed an electronic search of the MEDLINE, 
CINAHL, and Cochrane Library databases up to June 2021. 
Reference lists of retrieved studies were also examined 
along with ClinicalTrials.gov registrations for trials in pro-
gress. The search included MeSH terms and keywords 
relating to the topic of the review, which can be found in the 
online supplementary material. Examples include: 
‘Peripheral Arterial Disease’, ‘intermittent claudication’, 
‘PAD’, ‘home-based exercise’, ‘home-based training’, and 
‘walking programme’. 
Data extraction and management 
Search results were first imported into the reference man-
agement software Endnote (version X9.3.3, Clarivate 
Analytics) for duplicate removal, before being transferred 
to Covidence (version v2698, Veritas Health Innovations) 
for screening. Titles and abstracts of imported studies were 
reviewed independently by two researchers (AW and SS), 
with conflicts being resolved by a third (AH). The full texts 
of included studies were subsequently reviewed and data 
were collected on the study population, number of partici-
pants, frequency, duration, and content of exercise sessions, 
number of adverse events, and drop out/loss to follow up. If 
data were unclear regarding adverse events or reasons for 
drop out, the authors were contacted for clarification. If no 
clarification was received, these studies were excluded, a 
decision based on the methods of Gommans et al.18 
Outcomes 
The main outcome of interest was complication rate, calcu-
lated using Microsoft Excel as the number of adverse 
events deemed directly related to exercise participation, per 
patient-hours. The number of patient-hours was calculated 
as the number of participants multiplied by the number of 
exercise sessions, corrected for the average session dura-
tion.18 Studies that did and did not include pre-exercise car-
diac screening were separated to assess any differences in 
exercise-related event occurrence. This was also performed 
for studies with exercise prescribed at low, moderate and 
high levels of claudication pain. 
Risk of bias 
Depending on the research design, bias was assessed using 
either the ‘Revised Cochrane Risk-of-Bias Tool for 
Randomised Trials’20 or the ‘Risk Of Bias in Non 
Randomised Studies – of Interventions’ (ROBINS-I).21 
Risk of bias was assessed independently by two reviewers 
(AW and SS), with disagreements settled with discussion or 
by a third reviewer (AH). Bias was classified as either low, 
some concerns, or high. 
Results 
Study selection 
A search of the literature identified a total of 8693 studies, 
of which 27 were included in the full review following 
screening (online supplementary material). Twelve of the 
included studies were randomised controlled trials,22–33 and 
the remaining 15 were nonrandomised.34–48 The included 
studies comprised a total of 2351 participants, 1642 of 
whom received a home-based intervention, representing a 
total of 147,810 patient-hours. 
Participants 
The mean age of participants was 67 ± 2 years, ranging 
from 64 to 72 years, and, on average, 67% were male. All 
studies included participants with symptomatic IC. One 
study also included atypical leg symptoms, such as ischemic 
leg pain in the buttocks or thigh.26 In the included studies, 
common reasons for excluding participants were a walking 
limitation other than PAD, having had a revascularisation 
procedure in the last 3 months, foot ulcers, critical limb 
ischemia, active cancer treatment, an inability to walk 
unaided, and ischemic pain at rest. 
Study characteristics 
Ten of the included studies were performed in North
America, with the remaining studies being conducted


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Comparison of complication rates when undertaking 
a supervised or home-based exercise programme. 










aSupervised exercise complication rates taken from Gommans et al.18 
from 4 to 52 weeks, with a 12-week programme being the
most common (11/27 studies). Exercise session duration
was between 30 and 60 minutes and were completed over
3–7 days per week. Exercise programmes in all the
included studies consisted of walking, with one utilising
music to guide participants,34 one using walking poles,33 
and one using resistance band exercises in addition to
walking.35 The description of exercise location was varied,
including at home, an unsupervised setting, in the commu-
nity, a self-chosen environment, an outdoor track, or was
not specifically stated. Exercise intensity was generally
prescribed via claudication pain. We separated pro-
grammes based on the degree of claudication pain exercise
was prescribed at. Six of the studies described the claudi-
cation pain as near maximal, severe or intense, and were
classed as ‘high pain’.23–26,39,46 There were nine pro-
grammes with exercise that was pain-free, near the pain
threshold, or at maximal asymptomatic speed, which were
classed as ‘low pain’.26,28,32,33,42–45,47 Nine studies included
exercise to moderate pain levels.27,29,30,35–38,40,41 Two stud-
ies did not provide a clear description of the degree of
claudication pain22,34 and two did not report this
information.31,48 
Adverse events 
Potentially related adverse events were clearly reported in
studies.22,23,25,26,28,31–33,36,39,41–43,4614 of the included 
The remaining 13 studies reported no
events.24,27,29,30,34,35,37,38,40,44,45,47,48 Four related adverse
events occurred in total (three cardiac and one noncardiac in
origin) resulting in a total all-cause event rate of one event
per 36,953 patient-hours (Table 2). The total cardiac and
noncardiac event rates were one per 49,270 and one per
147,810 patient-hours, respectively (Table 2). Three of the
events occurred in a programme prescribing exercise to high
levels of claudication pain, and one event in a programme at
low pain levels. Six studies employed pretraining cardiac
screening consisting of cardiopulmonary exercise testing
(CPET) with electrocardiography (ECG) and/or expired gas
analysis.24,27–30,44 There were no related adverse events
reported in studies employing pretraining cardiac screening. 
Risk of bias 
Risk of bias assessments are reported in the online supple-
mentary material. Some concerns were raised in five stud-
ies due to inadequate information regarding the 
randomisation process24,30 or the allocation sequence con-
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bias due to missing data, with an imbalance in reasons for 
withdrawal in one36 and a large amount of imputed data in 
another.32 Five studies raised some concerns over the pos-
sibility of measurement of the outcome being influenced by 
knowledge of group allocation, as they required judge-
ments from participants aware of their interven-
tion.32,35,41,43,47 Three studies were deemed at high risk of 
bias due to selective reporting, with two missing question-
naire data22,23 and one not reporting all time points for 
treadmill data.41 One study was deemed at high risk of bias 
due to unclear group definition,44 and another raised some 
concerns as groups were created retrospectively.42 Two 
studies raised some concerns over deviations from the 
intervention, due to an imbalance in medication between 
groups creating a potential co-intervention38 and the inter-
vention not being delivered successfully in the majority of 
participants.46 
Discussion 
The aim of this review was to assess the safety of HBEPs in 
people living with IC by determining the number of exer-
cise-related adverse events. Previous research has indicated 
that SET is safe in this population;18 however, to our knowl-
edge, this is the first study to replicate these methods in 
HBEPs. In total, there were four related adverse events dur-
ing 147,000 patient-hours of exercise, resulting in an all-
cause event rate of 1 per 36,953 patient-hours. 
The all-cause event rate associated with HBEPs was 
considerably lower than SET, which has previously been 
reported as 1 per 10,340 patient-hours.18 Furthermore, the 
cardiac event rate following HBEPs was lower than in SET
(Table 2). There appears to be fewer adverse events after 
completing a HBEP, despite a potentially greater duration 
and frequency of training. However, this is likely a result of 
the exercise being completed at a self-selected pace (despite 
prescribed intensity), and thus participants may be less 
likely to experience an exercise-induced event. Despite 
this, in some cases, the safety of HBEPs may have been 
overestimated. The number of patient-hours was calculated 
based on the number and duration of training sessions pre-
scribed. However, not all participants complied with this 
prescription, which may mean the number of events under-
represents the true risk of full participation. Additionally, 
owing to the lack of supervision, it is likely that events may 
have not always been reported by participants. 
Gommans et al. determined there were no differences in 
the number of events when including or not including pre-
exercise CPET and ECG;18 thus, the authors of the review 
deemed it not to be clinically relevant. Although the 
American Heart Association recommends exercise testing 
to identify any exercise-induced coronary ischaemia,49 
existing best practice guidelines do not currently advocate 
CPETs in those with PAD.50 In our review, all related events 
occurred in studies not employing pre-exercise cardiac 
screening using ECG. More extensive screening may be 
more relevant prior to commencing HBEPs than SET, as 
participants are exercising alone without regular heart rate 
or blood pressure monitoring. In this case, more care may 
be needed to account for occult coronary artery disease, 
which may be exposed following the exercise programme 
as exercise tolerance improves. However, it is possible the 
imbalance in event occurrence with and without screening 
is due to the low proportion (21%) of studies utilising it. 
Three events were seen following exercise to high clau-
dication pain23,25,26 and the remaining event occurred fol-
lowing pain-free exercise.26 This may highlight concerns as 
the expanding literature of HBEPs covers exercise pre-
scribed at a range of claudication pain levels. For example, 
the current guidelines recommend walking to moderate-
maximal claudication pain,7,8 and there is increasing inter-
est in programmes prescribing pain-free walking.26,39,51 It is 
worth noting that by monitoring exercise intensity via clau-
dication pain, higher overall exercise workloads are likely 
not reached as individuals are symptom-limited before 
reaching higher equivalents of heart rate or oxygen uptake 
during which risk may be greater. However, previous 
research has shown that exercising at heart rates equivalent 
to claudication pain onset provides a tolerable stimulus that 
exceeds the anaerobic threshold, thus promoting cardiovas-
cular and metabolic adaptions.52 This is demonstrated by 
the majority of included studies having resulted in signifi-
cant improvements to walking performance. Asymptomatic 
individuals may be able to reach higher workloads without 
being limited by claudication pain, and so may be at a 
greater risk of cardiovascular events than those with classic 
IC symptoms. This is important when considering the 
safety of exercise for PAD in the wider population, as clas-
sic IC (calf cramp and pain during exertion) is not experi-
enced by all people living with PAD.53 
Interestingly, despite the exercise programmes in the 
included studies being described as home-based, the loca-
tion of the exercise varied. Locations mentioned included: 
in the home, the community, in a chosen environment, or 
on an outdoor track, with the majority not giving a clear 
description. It can be argued that exercise that does not take 
place inside or within the vicinity of the home (including 
driveways and gardens) is not home-based. Related adverse 
events occurring during exercise that do not fall in line with 
this definition would therefore not represent the safety of a 
HBEP. Differences in external factors such as the quality of 
the walking surface, access to areas to sit down, obstacles 
that exacerbate leg pain, and weather will not be consistent 
and may potentially influence the risk to the participant’s 
safety.54 
Study limitations 
This review is not without limitations. The description of 
exercise programmes was unclear at times making it diffi-
cult to ascertain if the programme was really home-based. 
The accuracy of calculating the total number of patient-
hours was impeded by lack of clarity, including some pro-
grammes increasing exercise session duration over the 
course of the programme but not providing specifics. Also, 
frequency of training was prescribed and reported as a 
range rather than as a specific number of days per week. 
Although potentially related adverse events were reported 
in 14/27 studies, the relatedness was decided by our inter-
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we deemed unrelated may in fact have been due to exercise, 
leading to the potential for some misclassification. Not all 
authors of studies with potentially related events responded 
to our emails, meaning certain HBEPs which may have 
altered the results had to be excluded. Additionally, strict 
participant exclusion criteria likely reduce the ability to 
generalise the results. As this clinical population tend to be 
highly co-morbid, an overestimation of the safety of exer-
cise programmes may be potentially harmful. As improve-
ments to exercise tolerance occur, patients may begin to 
experience previously unseen symptoms of coronary artery 
disease, presenting further concerns over safety. However, 
owing to such a low event rate, it is unlikely that the 
increase in adverse events, when not excluding more at-risk 
participants, will outweigh the benefits to walking perfor-
mance, mortality or quality of life seen with exercise pro-
grammes. Despite the limitations of our review, we are 
confident in the findings owing to rigorously following 
standardised operating procedures and reaching consensus 
at times of conflict and uncertainty. 
Conclusion 
The present review adds to existing evidence regarding the
safety of exercise in people living with IC. The complication
rates associated with HBEPs are lower than those with SET,
which were already reported to be extremely low. Pre-exercise
cardiac screening via CPETs may be more advisable in
HBEPs than SET; however, due to the lack of programmes in
this review that included a CPET, this remains unclear.
Prescribing exercise based on claudication pain level likely
means workloads where participants are at greater risk are not
reached. Future research should, therefore, assess whether
exercise in asymptomatic patients who may be able to tolerate
these greater workloads, is as safe as in those with IC. 
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